(Nasdaq: MDCX) Is A Low Float Biotech Profile Backed By 5 Key Potential Catalysts (On Radar)

In the life sciences arena, where progress moves quickly

*Disseminated on behalf of Medicus Pharma Ltd. (Nasdaq: MDCX) Is A Low Float Biotech Profile Backed By 5 Key Potential Catalysts (On Radar) September 19th Dear Reader, In the life sciences arena, where progress moves quickly, a handful of organizations are emerging for their efforts to create innovative therapies addressing critical, unmet health challenges. One of these companies, through its fully owned subsidiary, is advancing a dissolvable microneedle patch designed to deliver chemotherapy directly into tumors, with the goal of transforming treatment for skin cancers such as basal cell carcinoma. Currently under clinical evaluation in the U.S. and the United Arab Emirates, this approach could redefine cancer therapy by providing a less invasive, more patient-centered alternative to surgery or systemic drugs. The company is also expanding its presence through targeted acquisitions, including a late-stage biotech in the UK specializing in next-generation treatments for advanced prostate disease. These strategic steps underscore a broader objective: to impact multiple therapeutic fields, especially where safer and more effective approaches are lacking. Guided by a research-driven model and strengthened by extensive industry networks, the company is working to accelerate both development and market entry for innovative therapies. Amid the rapid growth of the global biotechnology sector, such initiatives stand out for their potential to establish new standards of care across human and veterinary medicine. And with a float of fewer than 3Mn, a freshly completed acquisition hot off the press, and multiple analyst targets suggesting massive upside potential, this Nasdaq profile has just overtaken my watchlist once again. What's that? Oh, yeah! This profile was previously alert only to watch it move approximately 28% from an August 18th open of $2.10 to a recent $2.69 high. Take a moment to consider this idea for your radar: *Medicus Pharma Ltd. (Nasdaq: MDCX)* Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. And based on several potential catalysts, (Nasdaq: MDCX) has pushed its way to the top of my watchlist. Take a look: No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - A Game-Changing Acquisition Gets Completed! No. 3 - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!). No. 4 - A Significant Update Shares Progression In Key Phase 2 Clinical Study. No. 5 - Medicus Signs MOU With Helix Nanotechnologies Inc. To Combine Key Company Platforms. But more on those in a second... Company Breakdown - Medicus Pharma Ltd. (Nasdaq: MDCX) Medicus Pharma Ltd. specializes in rapidly moving forward the clinical development of cutting-edge therapeutic solutions within the biotech and life sciences sector. About SkinJect - Medicus Pharma's (Nasdaq: MDCX) Wholly Owned Subsidiary A novel non-invasive regimen to treat skin cancer; especially Basal Cell Carcinoma. SkinJect Inc. is a development stage biotechnology life sciences company focused on commercializing novel treatment for non-melanoma skin cancer, especially basal cell carcinoma, using a patented dissolvable doxorubicincontaining microneedle arrays (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The relevant US Patents were granted to University of Pittsburgh and Carnegie Mellon University in 2018. SkinJect Inc. secured exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. The company attempts to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting. SkinJect Inc. has completed a Phase I study in March 2021 for participants with superficial and nodular Basal Cell Carcinoma (BCC). In January 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that is expected to randomize up to 60 patients. Patient recruitment began in August 2024 in 9 sites across the United States. A positively trending interim analysis in March 2025 showed more than 60% complete clinical response. In April 2025, IRB approved an increase in the number of patients from 60 to 90. SkinJect Clinical Development Outlook The SkinJect Value Proposition 1. Innovative Microneedle Patch Technology: The company aims to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting. Patented technology for non-invasively treating skin cancer using cellulose-based microneedles to deliver cancer drugs directly to the tumor site Exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. 2. Market Potential: BCC is the most common and fastest-growing cancer globally. >US$15Bn market for skin cancer treatments in North America by 2030. (1) Potential for further market expansion and penetration by SkinJect’s novel treatment approach. 3. Positive Clinical Trial Results: Phase 1 trial completed March 2021, demonstrating safety and tolerability. In Q1 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study. In Q3 2024 Phase 2 enrollment began. In Q1 2025 conducted interim analysis after 50% patient recruitment. In Q2 2025, IRB approved to increase number of patients from 60 to 90. 4. Seasoned Leadership and Board: Management team with public company experience. Board includes industry veterans and experts in oncology and drug development. Grab Key Sources: MDCX Presentation. MDCX Website. ----- And as I mentioned previously, (Nasdaq: MDCX) has several potential catalysts that could generate breakout buzz. Check them out: No. 1 MDCX Potential Catalyst - A Low Float Could Create The Environment For Heightened Volatility. According to info from the Finviz website, MDCX has a fairly low float. The website reports this profile to have roughly 2.56Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears towards the end of 2025, could it provide a breakout spark based on such a low float? ----- No. 2 MDCX Potential Catalyst - A Game-Changing Acquisition Gets Completed! Medicus Pharma Ltd. Completes Acquisition of Antev Limited Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6Bn in potential market opp. Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), ..., and Antev Limited ("Antev"), a UK-based clinical-stage drug development company, announced today that Medicus has acquired 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately US$2.97Mn in ca-sh and 1,603,164 common shares of Medicus, pursuant to the previously announced securities exchange agreement among Medicus, Antev and certain securityholders of Antev, dated as of June 29, 2025, as amended. Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Antev's former shareholders will be entitled to receive up to approximately US$65Mn in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals. Following the completion of the acquisition, Patrick J. Mahaffy, a veteran pharma executive and the former chairman of Antev, was unanimously appointed to Medicus's board of directors. Mr. Mahaffy is also the former CEO of both Clovis Oncology (NASDAQ: CLVS) and Pharmion Corporation (NASDAQ: PHRM). ... "We are delighted to complete the acquisition of Antev, which not only adds strategic depth to our drug development pipeline but also strengthens our team, both at the board and management level," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "We believe, Teverelix, a next generation GnRH antagonist, is well positioned to become a first in class product to prevent acute urinary retention relapse due to enlarged prostate, and to treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing approximately US$6Bn in potential market opp." ... Read the full article here. ----- No. 3 MDCX Potential Catalyst - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!). Check out what MarketBeat is reporting: As of Thursday's close, MDCX had two different analyst targets pointing to a significant amount of upside potential. Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 900% from Thursday's close. Additionally, Jason McCarthy of Maxim Group has provided a $20 target suggesting 600+% potential upside from Thursday's close. Most recently, Zacks Research provided MDCX with an "Upgrade" just this week. Could (Nasdaq: MDCX) be undervalued from current chart levels? ----- No. 4 MDCX Potential Catalyst - A Significant Update Shares Progression In Key Phase 2 Clinical Study. Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that the SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi (CCAD). Earlier this year, in May 2025, SKNJCT-004 received "study may proceed" approval from the UAE Department of Health. The study is expected to randomize thirty-six (36) patients in four sites in UAE. In addition to Cleveland Clinic Abu Dhabi (CCAD), the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. "Commencing patient recruitment in the SKNJCT-004 clinical study at Cleveland Clinic Abu Dhabi is a promising step forward towards our goal to bring to market a first in class novel non-invasive alternative to treat BCC," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "We have already randomized more than seventy five percent (75%) of the ninety (90) participants expected to be randomized in our AI powered SKNJCT-003 study, in the United States, which we believe represents more than US$2Bn in potential market opp." ... Read the full article here. ----- No. 5 MDCX Potential Catalyst - Medicus Signs MOU With Helix Nanotechnologies Inc. To Combine Key Company Platforms. Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vac-cines The MOU intends to combine proprietary mRNA vac-cine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vac-cines and therapies to augment the immune system's power to fight disease, announced today that they have entered into a non-binding memorandum of understanding (the "MoU") in respect of their shared mutual interest in the development of thermostable infectious diseases vac-cines by combining HelixNano's proprietary mRNA vac-cine platform with Medicus' proprietary MNA delivery platform. ... "The potential of combining HelixNano's potent mRNA vaccine platform with our uniquely formulated dissolvable microneedle array (MNA) technology, is designed to unlock next generation vaccination paradigm," stated Dr. Raza Bokhari, Executive Chairman & CEO, "aiming to develop needle-free, thermostable vaccines that could eliminate cold-chain logistics, reduce distribution costs, improve patient access and offer global scale, which could potentially position us at the forefront of ground-breaking opportunities to prevent, rather than treat, infectious diseases. The Company is exploring numerous possibilities offered by microneedle arrays." ... Read the full article here. ----- (Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - A Game-Changing Acquisition Gets Completed! No. 3 - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!). No. 4 - A Significant Update Shares Progression In Key Phase 2 Clinical Study. No. 5 - Medicus Signs MOU With Helix Nanotechnologies Inc. To Combine Key Company Platforms. ----- Coverage is officially initiated on Medicus Pharma Ltd. (Nasdaq: MDCX). Be on the lookout for updates coming shortly. Sincerely, Jaks Swift Fierce Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/17/2025 and ending on 09/24/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid fifty two thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/mdcx-urxmf/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice